Consecutive 179 patients with chronic liver diseases who underwent gadoxetate enhanced-MRI and MDCT firstly developed hypervascular liver masses were retrospectively recruited, and 14 stroma-rich tumors (SRT), such as intrahepatic cholangiocellular carcinoma, and 165 hepatocellular carcinoma (HCC) were found. Using rim enhancement, and target sign on DWI, which were confirmed to favor SRT over HCC by multivariate analysis on gadoxetate-enhanced MRI, 71% sensitivity and 97% specificity were obtained, however, MDCT provided almost 100% accuracy when delayed or prolonged enhancement was considered signs suggesting SRT. For diagnosing SRT, MDCT outperforms gadoxetate-enhanced MRI.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords